share_log

Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $47

Benzinga Real-time News ·  Jan 23, 2023 07:12

Piper Sandler analyst David Amsellem maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and raises the price target from $40 to $47.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment